Equillium, Inc. (NASDAQ:EQ – Free Report) – Analysts at HC Wainwright raised their FY2024 earnings estimates for shares of Equillium in a report issued on Monday, August 19th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.62 for the year, up from their previous estimate of $0.55. HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for Equillium’s current full-year earnings is ($0.12) per share.
Equillium Price Performance
NASDAQ:EQ opened at $0.82 on Tuesday. The stock has a fifty day simple moving average of $0.75 and a 200 day simple moving average of $1.49. The firm has a market capitalization of $29.00 million, a price-to-earnings ratio of -2.29 and a beta of 1.82. Equillium has a 1-year low of $0.45 and a 1-year high of $3.25.
Institutional Trading of Equillium
About Equillium
Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.
See Also
- Five stocks we like better than Equillium
- Using the MarketBeat Dividend Yield Calculator
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- What is a SEC Filing?
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- How to Calculate Options Profits
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.